Search - tctmd.com

Displaying 21 - 40 of 98

Sort: Relevancy | Date

Presentation TCT 2017

TCT 101: Safety of Double Antiplatelet Therapy as an Alternative to Warfarin Plus Aspirin After Left Atrial Appendage Device Closure - Short-Term Results of WATCHMAN-DAPT Multi-Center Registry

Presenter: Brij Maini, Petr Neuzil, Grzegorz Smolka, MD

October 31, 2017

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

Presentation TCT 2017

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Roxana Mehran

October 30, 2017

Presentation TCT 2017

Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Thomas Engstroem

October 30, 2017

Presentation TCT 2017

Switching to and From Cangrelor: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Matthew J. Price

October 30, 2017

Presentation TCT 2017

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini

October 30, 2017

Presentation TCT 2017

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Ron Waksman

October 30, 2017

Presentation TCT 2017

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies!

Presenter: John A. Bittl, Freek W.A. Verheugt, Gennaro Giustino

October 30, 2017

Presentation TCT 2017

Expanding Clinical Evidence With SYNERGY: From EVOLVE II to Real-world Registries and EVOLVE DAPT

Presenter: Ioannis Iakovou, Gert Richardt, Dean J. Kereiakes

October 30, 2017

Presentation TCT 2017

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies!

Presenter: John A. Bittl, Freek W.A. Verheugt, Dirk Sibbing

October 30, 2017

Presentation TCT 2017

DAPT Duration After BVS: Can Evidence-Based Recommendations Be Made?

Presenter: John A. Bittl, Freek W.A. Verheugt, Davide Capodanno

October 30, 2017

Presentation TCT 2017

Debate: DAPT Duration With Contemporary DES: Short (<1 Year) DAPT for Most ACS Patients!

Presenter: John A. Bittl, Freek W.A. Verheugt, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

Debate: DAPT Duration With Contemporary DES: Prolonged (>1 Year) DAPT for Most ACS Patients!

Presenter: John A. Bittl, Freek W.A. Verheugt, Robert W. Yeh

October 30, 2017

Presentation TCT 2017

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Somjot S. Brar

October 30, 2017

Presentation TCT 2017

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Dimitrios Alexopoulos

October 30, 2017

Presentation TCT 2017

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

Presenter: Stephen G. Ellis, David E. Kandzari, Tullio Palmerini

October 30, 2017

Presentation TCT 2017

NSTEMI Case Presentation: Why the DAPT Pre-load Decision Matters

Presenter: John A. Bittl, Freek W.A. Verheugt, Patricia J. Best

October 30, 2017

Presentation TCT 2017

Should Choice of Parenteral Therapy for Primary PCI in STEMI Depend on Vascular Access?

Presenter: Michael S. Lee, Dirk Sibbing, John A. Bittl

October 30, 2017

Presentation TCT 2017

Parenteral Therapy in STEMI: Does VALIDATE Change the Equation?

Presenter: Michael S. Lee, Dirk Sibbing, David Erlinge

October 30, 2017

Advertisement

TCT 101: Safety of Double Antiplatelet Therapy as an Alternative to Warfarin Plus Aspirin After Left Atrial Appendage Device Closure - Short-Term Results of WATCHMAN-DAPT Multi-Center Registry

Long-term Absorb BVS Data Continue to Disappoint

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment

Switching to and From Cangrelor: When and How?

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies!

Expanding Clinical Evidence With SYNERGY: From EVOLVE II to Real-world Registries and EVOLVE DAPT

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies!

DAPT Duration After BVS: Can Evidence-Based Recommendations Be Made?

Debate: DAPT Duration With Contemporary DES: Short (<1 Year) DAPT for Most ACS Patients!

Debate: DAPT Duration With Contemporary DES: Prolonged (>1 Year) DAPT for Most ACS Patients!

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

NSTEMI Case Presentation: Why the DAPT Pre-load Decision Matters

Should Choice of Parenteral Therapy for Primary PCI in STEMI Depend on Vascular Access?

Parenteral Therapy in STEMI: Does VALIDATE Change the Equation?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content